Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review

Blood20.30
Volume: 134, Issue: Supplement_1, Pages: 5556 - 5556
Published: Nov 13, 2019
Abstract
Introduction Amyloidosis is a rare disease and there are currently no FDA approved therapies for AL amyloidosis. Most of the therapeutic and disease data come from expert guidelines, consensus and retrospective review papers. There is a paucity of data specifically for relapsed/refractory AL amyloidosis (RRAL). We conducted this systematic review of clinical trials, retrospective and prospective cohort studies to evaluate patterns of relapse and...
Paper Details
Title
Patterns of Relapse and Treatment for Relapsed/Refractory AL Amyloidosis: A Systematic Review
Published Date
Nov 13, 2019
Journal
Volume
134
Issue
Supplement_1
Pages
5556 - 5556
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.